Short answer
Upstream Bio, Inc. (UPB) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Verekitug Phase 3 plans announced for severe asthma and chronic rhinosinusitis with nasal polyps.
Upstream Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Verekitug Phase 3 plans announced for severe asthma and chronic rhinosinusitis with nasal polyps
- Development update signals advancement toward pivotal clinical testing and potential regulatory submissions
- Press release furnished as Exhibit 99.1 for study design and timing details
Item 8.01 · Other Events
- Verekitug Phase 3 plans target severe asthma and CRSwNP, advancing the asset toward pivotal efficacy and regulatory testing
- One 400mg subcutaneous dose every 12 weeks, with approximately 1,500 patients across both placebo-controlled trials
- Broad enrollment without baseline biomarker restrictions could support wider commercial positioning if efficacy is confirmed
- Trials planned to start Q1 2027; potential BLA submissions and launch as early as 2030 remain contingent on results and FDA review
- Key risks include trial outcomes, FDA acceptance, funding needs, manufacturing partners, and competition
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 trials planned for severe asthma and CRSwNP, marking verekitug’s transition into pivotal late-stage development
- 400mg subcutaneous dose every 12 weeks, targeting quarterly administration and broad populations regardless of biomarker status
- Approximately 1,500 patients across both placebo-controlled trials, with initiation targeted for Q1 2027
- Primary endpoints: 48-week annualized asthma exacerbation rates; CRSwNP nasal polyp and congestion scores
- Potential BLA submissions for both indications and U.S. launch as early as 2030, contingent on supportive results
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Upstream Bio, Inc. 8-K filings
Get the next UPB 8-K as it lands
Follow UPB for push alerts, or ask the research agent what this filing means.